Vinitsky, A., Chiang, J., Bag, A. K., Campagne, O., Stewart, C. F., Dunphy, P., Shulkin, B., Li, Q., Lin, T., Hoehn, M. E., Johnson, J. N., Towbin, J. A., Khan, R., Tatevossian, R. G., Armstrong, G. T., Potter, B., Conklin, H., Shearer, T., Scott, S., & Robinson, G. W. (n.d.). lGG-22. SJ901: Phase I/II evaluation of single agent mirdametinib (PD-0325901), a brain-penetrant MEK1/2 inhibitor, for the treatment of children, adolescents, and young adults with low-grade glioma (LGG). Neuro-oncology, 24, i92. http://access.bl.uk/ark:/81055/vdc_100156448889.0x000027